These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12064312)

  • 1. Saquinavir with low-dose ritonavir twice daily.
    TreatmentUpdate; 2002; 14(4):2-3. PubMed ID: 12064312
    [No Abstract]   [Full Text] [Related]  

  • 2. Searching for the right dose of ritonavir-saquinavir.
    TreatmentUpdate; 2001 Sep; 13(5):3. PubMed ID: 11768860
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA notifications. Potential serious effect of combination saquinavir-ritonavir.
    AIDS Alert; 2010 Apr; 25(4):45-6. PubMed ID: 20564774
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin.
    Losso MH; Lourtau LD; Toibaro JJ; Saenz C; González C
    Antivir Ther; 2004 Dec; 9(6):1031-3. PubMed ID: 15651762
    [No Abstract]   [Full Text] [Related]  

  • 5. Saquinavir plus ritonavir reduce viral load by 99.9 percent.
    Vazquez E
    Posit Aware; 1996; 7(6):8-9. PubMed ID: 11363983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patient's guide to protease inhibitors.
    Elperin A; Sax P
    AIDS Clin Care; 1996 Oct; 8(10):83-4. PubMed ID: 11363988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saquinavir/low-dose ritonavir: its use in HIV infection.
    Johnson M; Peters B
    AIDS Rev; 2003; 5(1):44-51. PubMed ID: 12875107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg.
    Ananworanich J; Siangphoe U; Mahanontharit A; Hill A; Hirschel B; Ruxrungtham K
    Antivir Ther; 2004 Dec; 9(6):1035-6. PubMed ID: 15651763
    [No Abstract]   [Full Text] [Related]  

  • 10. [Ritonavir/Saqinavir: dual protease inhibitor combination. Salvage therapy].
    MMW Fortschr Med; 2000; 142(3 Suppl):41. PubMed ID: 11012293
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir.
    Manosuthi W; Sungkanuparph S; Ruxrungtham K; Prasithsirikul W; Athichathanabadi C; Tantisiriwat W; Bowonwatanuwong C; Chumpathat N; Chaovavanich A
    J Acquir Immune Defic Syndr; 2008 Jan; 47(1):127-9. PubMed ID: 18156994
    [No Abstract]   [Full Text] [Related]  

  • 12. [New formulation--fewer tablets--optimal effect].
    Krankenpfl J; 2005; 43(7-10):249. PubMed ID: 16515318
    [No Abstract]   [Full Text] [Related]  

  • 13. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of saquinavir/ritonavir in HIV-infected pregnant women: INEMA cohort.
    Brunet C; Reliquet V; Jovelin T; Venisse N; Winer N; Bui E; Le Moal G; Perfezou P; De Saint Martin L; Raffi F
    Med Mal Infect; 2012 Sep; 42(9):421-8. PubMed ID: 22938775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute hepatitis in a patient treated with saquinavir and ritonavir: absence of cross-toxicity with indinavir.
    Vandercam B; Moreau M; Horsmans C; Gala JL
    Infection; 1998; 26(5):313. PubMed ID: 9795794
    [No Abstract]   [Full Text] [Related]  

  • 16. Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients.
    Hellinger J; Cohen C; Morris A; Sheble-Hall S; Gordon D; Foy C; Jackson-Pope L; Shevitz A; van Schaic E
    HIV Clin Trials; 2005; 6(2):107-17. PubMed ID: 15983895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saquinavir/Ritonavir: its evolution and current treatment role.
    O'Brien WA
    AIDS Read; 2006 Jan; 16(1):38-44; discussion 43. PubMed ID: 16433471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response.
    Nieuwkerk P; Gisolf E; Sprangers M; Danner S;
    Antivir Ther; 2001 Jun; 6(2):97-103. PubMed ID: 11491422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From grapefruit juice to ritonavir.
    TreatmentUpdate; 2001; 12(12):5-6. PubMed ID: 11570093
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of a modified saquinavir/ritonavir dosing regimen with lower dose lead-in phase on QTc interval, pharmacokinetics, antiviral activity and safety in treatment-naïve HIV-1-infected patients.
    Boffito M; Jackson A; Pozniak A; Giraudon M; Kulkarni R; Abelardo MC; Patel IH; Morcos PN
    Drugs R D; 2015 Mar; 15(1):141-53. PubMed ID: 25742730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.